The maker of the controversial Alzheimer’s treatment aducanumab, aka Aduhelm, is abandoning its license for the drug. The U.S. Food and Drug Administration approved Aduhelm, made by Biogen, in 2021 despite its own statisticians and an independent advisory body concluding that it likely didn’t work. It also carries significant risks of side effects. Aduhelm’s price was set at $56,000 a year, and many insurers including Medicare refused to cover it. Pharma veteran Derek Lowe called the approval “one of [the FDA’s] worst decisions” in his 30-year drug-industry career, but Alzheimer’s is such a frightening, intractable, and widespread disease that regulators and pharma companies are tempted to get a drug to market, however marginal its effects. |